International Liver Cancer Association (ILCA) Avenue de Tervueren, 300 B-1150 Brussels Belgium info@ilca-online.org+32 (0)2 789 2345 +32 (0)2 743 1550 |
Speakers, Sessions, Symposia
Inaugural ILCA Annual Conference, 5-7 October 2007, Barcelona, Spain
Program
|
|
State of the Art Sessions |
|
|
Symposia |
|
|
General Sessions |
|
|
Industry Symposia |
| TIME |
Friday, 5 October |
|
| 11:30-13:15 |
Biocompatibles Symposium
TACE in HCC: A multi-disciplinary overview
Chair: Jordi Bruix, Barcelona (Spain)
The scientific rationale for TACE and health/safety considerations
Irene Krämer, Mainz (Germany)
An overview of the clinical data
Josep M. Llovet, Barcelona (Spain) - New York (USA)
Device selection and delivery technique
Riccardo Lencioni, Pisa (Italy)
Oncology perspectives on the management of liver cancer
Michel Ducreux, Villejuif (France)
View Invitation Letter View Programme
|
Registration open
(09:00 - 18:00) |
| 13:15-13:30 |
Opening Ceremony |
Industry and Poster exhibition
(13:00 - 20:30)
|
| 13:30-15:00 |
General Session I
Oral Communications
O-001 Living donor liver transplantation for hepatocellular carcinoma; experience with 653 cases in
O-002 Grading of microvascular invasion by hepatocellular carcinoma treated by rhepatic resection
Presenting author: Sasan Roayaie
O-003 Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus
Presenting author: Kiyoshi Hasegawa
O-004 Liver resection for intrahepatic cholangiocarcinoma
Presenting author: Sven Jonas
O-005 Predictors of dropout from transplant waiting list among patients listed for hepatocellular carcinoma using the UNOS/OPTN database
Presenting author: Carlos Romero Marrero
O-006 Liver transplantation as primary therapy for hepatocellular carcinoma in non-cirrhotic livers
Presenting author: Hynek Mergental |
| 15:00-16:00 |
State of the Art Session I
The Translational Lecture:
Chronic inflammation and cancer development
Chair: Gregory J. Gores, Rochester (USA)
Speaker: Curtis Harris, Bethesda (USA) |
| 16:00-16:30 |
Coffee Break |
| 16:30-18:00 |
General Session II
Oral Communications
O-007 A new prognostic subtype of hepatoblastoma defined by specific gene expression profile and genomic aberrations
Presenting author: Armengol
O-008 Expression of stemness gene Bmi-1 in hepatocellular carcinoma
Presenting author: Michiie Sakamoto
O-009 Integrated profiling of DNA and RNA alterations in hepatitis C virus positive hepatocellular carcinomas
Presenting author: Derek Chiang
O-010 Survival gene signature for hepatocellular carcinoma (HCC) from high-throughput profiling of informative transcriptome in archived paraffin-embedded tissue
Presenting author: Yujin Hoshida
O-011 miRna expression profiling in benign and malignant liver tumors: correlations with clinical and genetic features
Presenting author: Yannick Ladeiro
O-012 A unique metastasis-related microRna expression signature is a prognostic indicator of survival and recurrence in hepatocellular carcinoma
Presenting author: Anuradha Budhu |
| 18:00-19:30 |
Bayer Schering Pharma Symposium
Recent advances with targeted therapies: a new era in the management of hepatocellular carcinoma
Chair: Jordi Bruix, (Spain)
Welcome and introduction
Jordi Bruix, (Spain)
Hepatocellular carcinoma: current approaches to management
Jordi Bruix, (Spain
Targeting the underlying molecular mechanisms of hepatocellularcarcinoma
Gregory J. Gores, (USA)
Management of hepatocellular carcinoma: recent advances and futureprospectsJosep M. Llovet, (Spain) - (USA)
Discussion and concluding remarks
View programme (PDF) |
| 20:00-21:00 |
Welcome Reception | |
Back to top
| TIME |
Saturday, 6 October |
|
09:00-10:30
|
General Session III
Oral Communications
O-013 Stromal regulation of hepatocarcinogenesis: PDGF receptors as a target for therapy
Presenting author: Nelson Fausto
O-014 Molecular and functional dissection of the insulin-like growth factor (IGF)-II signalling pathway in human hepatocarcinogenesis
Presenting author: Kay Breuhahn
O-015 Smad interacting protein SIP1 acts as a negative regulator of growth in hepatocellular carcinoma cells
Presenting author: Ayca Arslan-Ergul
O-016 Homozygous deletion of p53 induces liver cancer exhibiting stem cell characteristics
Presenting author: André Lechel
O-017 Integrative genomic analysis of PI3K/AKt/mTOR pathway in hepatocellular carcinoma: clinical outcome implications
Presenting author: Augusto Villanueva
O-018 Sorafenib inhibits the Raf/MEK/ERK pathway and angiogenesis, induces apoptosis and produces robust efficacy in preclinical models of hepatocellular carcinoma (HCC)
Presenting author: Lila Adnane |
Registration open
(09:00 - 14:00)
|
| 10:30-11:00 |
Coffee Break |
Industry and Poster exhibition
(10:30 - 18:00) |
| 11:00-13:00 |
Symposium I
Future prospects in clinical research in HCC
Chairs:
Pierre-Alain Clavien, Zürich (Switzerland)
Ding-Shinn Chen, Taipei (Taiwan)
Review of current guidelines for clinical practice and research
Jordi Bruix, Barcelona (Spain)
New markers for screening and diagnosis
Laura Beretta, Seattle (USA)
Emerging molecular targeted therapies
Andrew X. Zhu, Boston (USA)
Principles of trial design in HCC research
Josep M. Llovet, Barcelona (Spain) - New York (USA) |
| 13:00-14:00 |
Bracco Symposium
Focal liver lesions - The key role of contrast enhanced UltraSound (CEUS) modality for diagnosis and early assessment of treatment efficacy
Chair: Riccardo Lencioni, Pisa (Italy)
Clinical guidelines - The consensus opinion of experts as regard to the role of CEUS modality in liver imaging
Riccardo Lencioni, Pisa (Italy)
STIC study for focal liver lesion diagnosis - Take-home messages from a large multicenter clinical trial using CEUS in comparison to MDCT and CEMRI
François Tranquart, Tours (France)
The use of CEUS during liver surgery - Its impact on operative outcome
Guido Torzilli, Milan (Italy)
|
| 13:00-15:00 |
Lunch and Poster Viewing |
| 15:00-16:30 |
Business Meetings for
ILCA Members |
| 16:30-17:00 |
Coffee Break |
| 17:00-19:00 |
General Session IV
Oral Communications
O-019 Activity of sunitinib in patients with advanced hepatocellular carcinoma (HCC): an international phase II trial
Presenting author: Sandrine Faivre
O-020 Long acting octreotide in the treatment of advanced hepatocellular carcinoma and overexpression of somatostatin receptors. A randomized placebo-controlled trial
Presenting author: Dimitrios Dimitroulopoulos
O-021 A phase II study of sunitinib in patients with advanced hepatocellular carcinoma
Presenting author: Andrew Zhu
O-022 Sorafenib improves survival in hepatocellular carcinoma: results of a phase III randomized placebo-controlled trial
Presenting author: Jordi Bruix
O-023 A randomized trial comparing 3-month vs. 6-month screening for HCC by ultrasonography in cirrhosis
Presenting author: Jean Claude Trinchet
O-024 Four decades’ studies on hepatocellular carcinoma – from bench to bedside
Presenting author: Zhao-You Tang |
| |
Back to top
| TIME |
Sunday, 7 October |
|
| 08:30-09:00 |
IARC's research agenda for combating liver cancer worldwide |
|
| 09:00-11:00 |
Symposium II
Signal transduction pathways in liver tumors
Chairs:
Peter Galle, Mainz (Germany)
Kazuhiko Koike, Tokyo (Japan)
Signaling pathways in the pathogenesis of HBV and HCV-related HCC
Jack R. Wands, Providence (USA)
Telomere shortening, cirrhosis, and cancer
Lenhard Rudolph, Hannover (Germany)
The wnt canonical pathway in benign and malignant liver tumors
Jessica Zucman-Rossi, Paris (France)
Linking signaling pathways and clinical outcomes in liver cancer
Snorri Thorgeirsson, Bethesda (USA)
|
Industry exhibition
(09:00 - 14:00) |
| 11:00-11:30 |
Coffee Break |
| 11:30-12:30 |
State of the Art Session II
The Clinical Lecture:
Past, present and future of surgical management of HCC
Chair: Vincenzo Mazzaferro, Milan (Italy)
Speaker: Masatoshi Makuuchi, Tokyo (Japan) |
| 12:30-14:00 |
General Session V
Oral Communications
O-025 Outcome and prognostic factors of untreated hepatocellular carcinoma (HCC) on cirrhosis
Presenting author: Luisa Benvegnu
O-026 Detection of hypervascular foci in hypovascular borderline lesion upon cirrhotic liver: comparison of dynamic contrast enhanced multi-detector row CT, dynamic gadolinium-enhanced MR, and SPIO-enhanced MR imaging
Presenting author: Satoshi Kobayashi
O-027 Vessel invasion of hepatocellular carcinoma: can high risk factors be identified on preoperative CT scan?
Presenting author: Mi-Suk Park
O-028 Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin
Presenting author: Mina Komuta
O-029 Sequencing of HVRII and HVRIII of mitochondrial-DNA distincts between disseminated and synchronic hepatocellular carcinoma (HCC)
Presenting author: Maria Varela
O-030 Loss of heterozygosity at D8S298 is a predictor for long-term survival of patients with TNM stage I of hepatocellular carcinoma
Presenting author: Lun-Xiu Qin | |
Back to top |
Conference
Membership
ILCA – an International and Multi-disciplinary
Association for Liver Cancer Experts
Find out more about ILCA Member Benefits and how to become a member.
Association
Mission
The International Liver Cancer Association (ILCA) aspires towards advancing research in the pathogenesis, prevention, and treatment of liver cancer.
|
